Abstract:Abstract Background: Colorectal cancer (CRC) is the 3rd most diagnosed cancer worldwide. Early detection and correct patient stratification are important components for cancer prevention, diagnosis, and successful treatment. Cell-free DNA (cfDNA) fragment sizes have been previously shown to differ between cancer and non-cancer patients, while loss of heterozygosity is one of the major types of genetic inactivation, with long arm of chromosome 18 being most frequently reported to be deleted in CRC patients. We are here looking at the cfDNA fragmentation signal in early-stage CRC in the context of 18q21 region reported to exhibit copy number variations (CNV). Methods: This was a prospective, international multicenter observational cohort study. Plasma samples were collected either prior to a scheduled colonoscopy as part of standard colorectal cancer screening or prior to colonic surgery for primary CRC in several hospitals in Spain, Germany and Ukraine. Samples were prepared and analyzed with whole genome enzymatic sequencing approach in 2 separate sets (Training Set and Testing Set). Training set consisted of 24 CRC patients (3 stage 0, 10 stage I, 5 stage IIA, 3 stage III, 2 stage IIIA and 1 stage IIIB) and 24 matching controls. The proportion of aligned short fragments over the total number was computed for Chr18q21 based on pre-defined bins. From the total number of binned regions, those presenting an average correlation with the others >0.5 were discarded, getting a final set of regions, which were used as the input data of the Linear Discriminant Analysis (LDA) model. LDA model was then applied to independent Testing Set consisted of 12 CRC patients (4 stage I, 4 stage IIA and 4 stage III) and 12 matching controls. Results: Training Set analysis exhibited significant differences over whole Chr18q21 region, when comparing CRC and matching control patients. The 2959 region bins selected in the Training Set were used as the input data of the LDA model to test the performance. Model performance on an independent Testing set reached 83% sensitivity (10/12) at 92% specificity (11/12), with stage I sensitivity being as high as 75% (3/4) and stage IIA 100% (4/4). Sensitivity per cancer location was comparable with 83% sensitivity for proximal cancers (5/6) and 83% for distal cancers (5/6). Specificity was not affected by presence of benign findings such as hyperplastic polyps, diverticulosis/diverticulitis or hemorrhoids. Conclusions: The study results indicate that combining CNV information with the cfDNA fragment size information could serve as a promising new avenue for early detection of colorectal cancer, with early-stage (I-II) CRC sensitivity of 87.5% at 92% specificity. Larger cohort validation of these results is in progress. Citation Format: Pol Canal Noguer, Iva Cernosa, Fernando Trincado Alonso, Kristi Kruusmaa. Cell-free DNA (cfDNA) fragmentation profiles linked to copy number alteration analysis allows for early colorectal cancer detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3353.

Application of PCR-based approaches for evaluation of cell-free DNA fragmentation in colorectal cancer

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

Unraveling cfDNA Fragmentation Patterns: Linking Chromatin Architecture to Cancer Diagnostic Sensitivity

Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR

Abstract 3353: Cell-free DNA (cfDNA) fragmentation profiles linked to copy number alteration analysis allows for early colorectal cancer detection

Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays

Use of Enzymatically Converted Cell-Free DNA (cfDNA) Data for Copy Number Variation-Linked Fragmentation Analysis Allows for Early Colorectal Cancer Detection

Abstract 3380: Use of liquid biopsy for detection of pathogenic variants in cell-free tumor DNA from patients with precursor lesions and colorectal cancer

Genome-wide cell-free DNA fragmentation in patients with cancer

Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer

Fragmentomics of cell-free DNA from targeted panels in genitourinary malignancies.

Ultra-short Cell-Free DNA Fragments Enhance Cancer Early Detection in a Multi-Analyte Blood Test Combining Mutation, Protein and Fragmentomics.

Challenges and Prospects of Cell-Free DNA in Precision Oncology

Dissecting cell-free DNA fragmentation variation in tumors using cell line-derived xenograft mouse

Analysis of a Cell-Free DNA-based Cancer Screening Cohort Links Fragmentomic Profiles, Nuclease Levels, and Plasma DNA Concentrations

Cell-free nucleic acid fragmentomics: A non-invasive window into cellular epigenomes

Cell-free DNA end characteristics enable accurate and sensitive cancer diagnosis

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA

Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology

Abstract 4950: Applying fragmentomics profiles of plasma cell-free DNA for breast cancer detection

DNA demethylation triggers cell free DNA release in colorectal cancer cells